Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1652W HIGH $5.25
Volume
18.83 M
Value Traded
587.97 K
Short % Float
1.08%
Days to Cover
1.0
-5.96%Week
-29.7%1 Month
-46.62%3 Month
-40.34%6 Month
-99.97%5 Year
-99.97%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
115.86 M
EPS (TTM)
-1.08
P/E Ratio
-1.35
Ent. Value
203.45 M
Total Shares
76.33 M
Float Shares
62.39 M
Insiders
46.90%
Institutions
4.02%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ATLN Catalyst Timeline
Dated clinical, regulatory and corporate events for Atlantic International Corp.
Past FDA Catalysts and PDUFA Decisions
How ATLN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every ATLN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Franke Guus Paul WilhelmChairman & CEO | Sell | 308,783 12,207,287 held | $1.00 | 07/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ATLN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ATLN for Q2 2026. | ||||
ATLN Institutional Ownership Trends
ATLN Short Interest
Shares sold short, counted twice a month.
1.08%
Short % of Float
of tradable shares sold short
1.2M
Shares Sold Short
+46.7% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
59.5M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ATLN ranks across every disease it competes in
Competitive Position is a premium feature
See how ATLN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialATLN News
About Atlantic International Corp.
Founded2014
BIOPHARMAWATCH ELITE PLUS
Trade the next ATLN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime